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Previous studies showed the presence of Mycoplasma pneumoniae (M. pneumoniae) and membrane-shed microparticles (MPs)
in vulnerable atherosclerotic plaques. H&S Science and Biotechnology developed PTCTS, composed by natural particles from
medicinal plants (PTC) combined with trans-Sialidase (TS), to combat MPs and Mycoplasma pneumoniae. Our aim was to
determine the effects of the different components of PTCTS in a rabbit model of atherosclerosis. Rabbits were fed with high
cholesterol diet for 12 weeks and treated during the last 6 weeks with either vehicle, PTC, TS, or PTCTS. Lipid profile and
quantification of MPs positive for Mycoplasma pneumoniae and oxidized LDL antigens were carried out. Aortas and organs were
then histologically analyzed. PTCTS reduced circulating MPs positive for Mycoplasma pneumoniae and oxidized LDL antigens,
reduced the plaque area in the abdominal aorta, and caused positive remodeling of the ascendant aorta. PTC caused positive
remodeling and reduced plaque area in the abdominal aorta; however, TS had a lipid lowering effect. PTCTS components combined
were more effective against atherosclerosis than individual components. Our data reinforce the infectious theory of atherosclerosis
and underscore the potential role of circulatingMPs.Therefore, the removal ofMycoplasma-derivedMPs could be a new therapeutic
approach in the treatment of atherosclerosis.
1. Introduction
Human atherosclerosis is a chronic systemic process, char-
acterized by the presence of arterial wall thickening due
to the accumulation of lipids, endothelial dysfunction, and
inflammatory and fibroproliferative responses, resulting in
the formation of atherosclerotic plaques, vascular prolifera-
tion, and extracellular matrix changes [1].
When levels of LDL rise in systemic circulation, they bind
to proteoglycans and increase their retention time in the arte-
arterial rial intima, settling on it, where they are oxidized by
free radicals, triggering the inflammation that damages the
endothelial barrier function, increasing thus vascular perme-
ability [2].
Previous studies from our laboratory have shown that, in
human atherosclerosis, Mycoplasma pneumoniae (M. pneu-
moniae) was present within the atherosclerotic plaques, with
greater quantities in vulnerable plaques, which broke and led
to acutemyocardial infarction,when associatedwithChlamy-
dophila pneumoniae [3]. Mycoplasmas are among the few
prokaryotes that can grow symbiotically with other microor-
ganisms, strongly interacting with mammalian host cells for
long periods [4].
When exposed to stress conditions, Mycoplasmas can
release microparticles (MPs) containing proteins and genetic
material from the originating cells as a response to such stress,
thus allowing their adaptation to various environments [5, 6].
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MPs are small vesicles of 100 nm to 1 𝜇m in diameter,
coated in membrane and released during cell activation or
apoptosis.They harbor membrane proteins of the parent cell,
which allows for their characterization according to their
cellular origin [7, 8]. The effects of MPs may vary between
procoagulant and proinflammatory properties, induction of
endothelial dysfunction by changes in nitric oxide (NO)
levels and in the metabolic pathway of prostacyclin, decrease
in expression ofNO synthase (NOS), stimulation of cytokines
release such as interleukin-8 (IL-8), IL-1𝛽, IL-6, and tumor
necrosis factor-𝛼 (TNF-𝛼), and the expression of cell adhe-
sion molecules [8, 9], among other actions, fundamental
to the formation and development of atheromatous plaque
[10].
To prevent and treat atherosclerosis, H&S Science and
Biotechnology developed a compound that was reported to
fightMPs, PTCTS (particulated trans-Sialidase), registered in
the US, INCI, under the name PTCTS (number 5-11-2013-
1386). The PTCTS compound consists of natural organic
particles (PTC) obtained from medicinal plants associated
with trans-Sialidase enzyme (TS). Methods of obtaining
and preparation are protected by patents granted in the
United States (number 7,914,781), United Kingdom (number
EP1296554B1), Canada (number CA2383850C), and Brazil
(number PI0101648-8).
Higuchi [11] proposed that the use of TS could lead to
the regression of the atherosclerotic process by eliminating
Mycoplasmas through its capacity of reallocating sialic acids,
a family of amino sugars, which are involved in cell-to-
cell interactions and signaling functions in hematopoietic,
immune, and nervous systems [12]. It is known that the sialic
acids act as binders for pathogen receptors, particularly to
siglecs (sialic acid-binding immunoglobulin like lectins) [13];
however, they are also important nutrients for the main-
tenance of Mycoplasmas [14]. Therefore, the relocation of
sialic acids from the environment close to the bacteria to the
surrounding siglecs would allow them to act as their ligands,
a way of eliminating such bacteria. Santos et al. [15] have
injected the PTCTS compound intramuscularly to rabbits
fed high cholesterol diet to induce atherosclerosis and could
regress the atherosclerotic process and reduce total choles-
terol and its fractions to normal serum levels [15]; however,
the underlying mechanisms and the relative contribution of
PTC and TS components to the observed effects are yet to be
investigated.
Therefore, the present project was designed to further
understand how the protective effects of PTCTS compound
are mediated and to decipher the relative contribution of
its individual components, PTC and TS, to the observed
effects against atherosclerosis in rabbits. In this study, we
specifically assessed the effects of PTCTS, PTC, and TS on
the regression of atheromatous plaques and the elimination
of MPs associated with M. pneumoniae and oxidized low
density lipoprotein (oxLDL) antigens from the serum of
atherosclerotic rabbits. We have also evaluated the potential
toxicity of these compounds in the kidneys, liver, and spleen
from these rabbits.
2. Materials and Methods
2.1. Study Design. Male and female white New Zealand
rabbits from the Central Animal Laboratory of the Faculty
of Medicine (University of Sao Paulo, USP) of approximately
60 days of age and weighing 3.0 ± 0.5 kg were used in the
present study. Animals were placed in stainless steel cages
appropriate to the species and maintained with specific food
for the species and water ad libitum, with light and dark
intervals every 14/10 hours.
The sample size was calculated according to Student’s dis-
tribution method described by Dunnett [16]. The following
formula was used:
𝑡 =
𝑋 − 𝜇
𝑠/√𝑛
. (1)
Based on previous similar experimental studies from our
group [15], we have obtained sample standard deviation (𝑠)
and the used value for 𝑡 was set at 2.447 for a 95% confidence
interval of a two-tailed analysis and 6 degrees of freedom.
Rabbits included in the study were randomly divided into
5 groups as follows:
(1) Normal diet group: negative control group (CNeg, 𝑛 =
6) which received 400 𝜇L of water/day instead of the
treatment
(2) High cholesterol diet group: positive control group
(CPos, 𝑛 = 6) which received 400 𝜇L of water/day
instead of the treatment
(3) High cholesterol diet treated with organic particles
group: (PTC, 𝑛 = 6) where animals were treated with
natural organic particles (300 𝜇L/day) during the last
six weeks of high cholesterol diet
The natural organic particles were obtained through
a mixture of the medicinal plants extracts (Ginkgo
biloba, Allium sativum, Zingiber officinale, and Den-
drobium moschatum), ethanol, and water, according
to the protocol described by Sousa et al. [17]. This
mixture was diluted in thermal water 1 : 10,000 for the
treatment administration
(4) High cholesterol diet treatedwith trans-Sialidase group:
(TS, 𝑛 = 5) where animals were treated with
the enzyme trans-Sialidase (1.62 × 10−7mg/mL),
100 𝜇L/day, during the last six weeks of high choles-
terol diet
(5) High cholesterol diet treated with PTCTS group:
(PTCTS, 𝑛 = 6) where animals were treated with
PTCTS (400 𝜇L/day) during the last six weeks of high
cholesterol diet
Data obtained from the group of animals fedwith normal diet
were used as reference values for healthy animals, while data
from positive control group, which received high cholesterol
diet for 12 weeks, without treatment, were used as reference
values for diseased animals.
Animals in all groups were maintained for 12 weeks
and then sacrificed at the Central Animal Laboratory of
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the Faculty of Medicine, University of Sa˜o Paulo, where the
samples were harvested for further study.
All procedures involving experimentation on animals
were performed in accordance with Guide for the Care and
Use of Laboratory Animals (1996, published by National
Academy Press, 2101 Constitution Ave. NW,Washington, DC
20055, USA). Animal research protocol was approved by the
local ethical review committee of the University of Sa˜o Paulo.
2.2. Diet and Treatment Preparation. For the preparation
of the hypercholesterolemic diet, it was enriched with 1%
cholesterol by spraying a solution containing powder choles-
terol (Sigma-Aldrich, Missouri, USA), ethyl ether (Labsynth,
Diadema, Brazil), and absolute ethanol (Labsynth, Diadema,
Brazil) on usual commercial feed in the ratio of 1 g of
cholesterol to each 100 g of feed.
Cholesterol was dissolved by adding 100mL of ethyl ether
and 50mL absolute ethanol/g under constant stirring. The
solution was mixed with the usual feed and left in exhaust
hood for complete evaporation of the solvents for 24 hours.
2.3. Blood Collection and Biochemical Analyses. At the begin-
ning of the experiment, prior to the start of the high choles-
terol diet, blood samples were collected from themarginal ear
vein of each animal for biochemical analysis of basal levels of
total cholesterol (TC) and fractions [HDL and non-HDL (n-
HDL) cholesterol] and triglycerides (TG). Similar procedure
was performed immediately before the start of treatment
with PCT, TS, or PTCTS and at the end of the experiment
following the sacrifice of the animals. Samples obtained were
named basal, pretreatment, and posttreatment, respectively.
Biochemical analyses of total cholesterol and its fractions
were performed at the Laboratory of Clinical Analysis, while
histology and immunofluorescence analyses were performed
at the Cardiac Pathology Laboratory, both at the Heart
Institute of the Faculty of Medicine, University of Sa˜o Paulo
(InCor-HCFMUSP).
2.4. Sacrifice of the Animals. The animals were sacrificed by
first administering intramuscularly an anesthetic (ketamine,
25–50mg/kg associated with xylazine 2–5mg/kg) in addition
to barbiturate (thiopental) to deepen the anesthetic action.
Following this, animals were injected with 3mL of potassium
chloride by intracardiac route. Animals were immediately
subjected to necropsy.
2.5. Histological Analyses of Aorta and Organs. Aorta was
dissected from the monoblock of organs, sectioned at its
root and iliac bifurcation. Cross sections along the aortic
root containing approximately 0.5 cm extension from the
ascending portion of the artery, 2mm above the bronchial
branches and 2mm below the renal arteries, were made, and
these fragments were then immediately embedded in paraffin
for histological analysis.
Then, paraffin blocks were sectioned with a microtome
into sections of 5 𝜇m of thickness. Sections were then
stained with hematoxylin and eosin (H&E) and scanned
by ScanScope CS System (Aperio Technology, Inc., CA,
USA) with an objective Olympus UPlanSAPO 20x attached
to the scanner that generated image files “.svs” that were
then analyzed by Aperio ImageScope View software (Aperio
Technologies, Inc., California, USA).
By means of the software aid, we measured at the ascend-
ing portion of aorta the external elastic lamina perimeter
(PE); the internal elastic lamina perimeter (PI); the area of the
middle layer (AM); potential lumen of the vessel (LP), vessel
lumen without the plaque; the real lumen of the vessel (LR),
vessel lumenwith the plaque; the area of atheromatous plaque
(AP); and the percentage of vessel obstruction (% Obs).
In the thoracic and abdominal portions, we evaluated the
total length of the fragment (Et), the length of the atheroma-
tous plaque base (Ep), and its total area (AP).
During the sacrifice, samples of liver, spleen, and kidneys
were fixed in 10% buffered formalin, pH 7.4, for 24 hours,
which were processed for embedding in paraffin.The paraffin
blocks were serially 5 um sectioned, stained with H&E,
scanned through ScanScope CS System (Aperio Technology,
Inc., CA, USA), and finally analyzed qualitatively in Aperio
ImageScope View software (Aperio Technologies, Inc., CA,
USA). The analysis of sections from these organs evaluated
the integrity of tissues and cells, the presence of lesions, and
cellular changes.
2.6. Immunofluorescence. Immunofluorescence technique
was used to quantify the numbers of MPs positive for
M. pneumoniae and oxLDL antigens. This analysis was
performed in the serum of animals from the different stages
of the protocol (i.e., at baseline, before the start of treatment,
and at the end of the treatment).
To separate MPs, total serum solution was mixed with H
medium (D-mannitol, sucrose, HEPES, and BSA) and then
centrifuged and thus separated into two phases: pellet and
supernatant. Both fractions were analyzed fresh. Immunoflu-
orescence analysis was performed on the supernatant where
MPs are present.
The serum supernatant from animals in each group
was incubated with primary antibody against oxLDL (clone
2C7OSF10 prepared and donated by Dr. Dulcineia Abdalla,
Faculty of Pharmaceutical Sciences, USP) or primary anti-
body against M. pneumoniae (clone B748M, Abcam, Cam-
bridge, MA, USA).
For detection, aliquots labeled with oxLDL antibody
were incubated with donkey anti-mouse secondary antibody
(Alexa Fluor 488 IgG H + L) (Life Technologies, Carlsbad,
CA, USA), while aliquots labeled with antibody against
M. pneumoniae were incubated with donkey anti-mouse
secondary antibody (Alexa Fluor 555, IgG H + L) (Life
Technologies, Carlsbad, CA, USA).
Images of immune-stained slides with their fluorophores
were captured in fluorescentmicroscope EVOS FLCell Imag-
ing System (Advanced Microscopy Group (AMG), Thermo
Fisher Scientific, Waltham, Massachusetts, USA) using an
objective of magnification ×20 and saved in JPG format to be
quantified with the IrfanView (Irfan Skiljan, Vienna, Austria)
software. The numbers of MPs were then quantified in two
blind fields (4 pictures from each) from each sample, with
magnification ×20.
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Table 1: Circulating levels of total cholesterol, HDL cholesterol, non-HDL (n-HDL) cholesterol, and triglycerides in serum from control
and treated groups at basal, pretreatment, and posttreatment phases. The difference between pretreatment and posttreatment stages (ΔT) is
represented. Data are expressed as mean ± SD. Comparison between groups was performed using a paired t-test.
Basal Pretreatment Posttreatment ΔT Basal × pre Pre × post
𝑃 𝑃
Total cholesterol (mg/dL)
CNeg 100 ± 85 88 ± 43 84 ± 55 −4 ± 17 0.32 0.58
CPos 65 ± 39 979 ± 274 1418 ± 383 439 ± 345 <0.001 0.03
PTC 74 ± 51 1183 ± 318 1534 ± 426 352 ± 586 <0.001 0.2
TS 74 ± 36 971 ± 145 960 ± 376 −9 ± 336 <0.001 0.95
PTCTS 89 ± 56 968 ± 293 1137 ± 273 169 ± 120 <0.001 0.02
HDL (mg/dL)
CNeg 37 ± 19 42 ± 17 32 ± 20 −10 ± 18 0.17 0.22
CPos 32 ± 17 506 ± 279 445 ± 131 −61 ± 193 0.004 0.47
PTC 32 ± 18 531 ± 91 487 ± 125 −44 ± 123 <0.001 0.42
TS 42 ± 14 615 ± 189 344 ± 137 −225 ± 205 0.001 0.03
PTCTS 39 ± 20 573 ± 158 442 ± 98 −131 ± 140 <0.001 0.07
n-HDL (mg/dL)
CNeg 63 ± 75 46 ± 31 52 ± 37 6 ± 14 0.26 0.33
CPos 33 ± 25 473 ± 193 973 ± 385 500 ± 256 0.002 0.005
PTC 42 ± 34 652 ± 292 1047 ± 375 395 ± 502 0.002 0.11
TS 32 ± 24 357 ± 206 616 ± 333 216 ± 246 0.01 0.08
PTCTS 50 ± 37 395 ± 395 696 ± 197 300 ± 229 0.01 0.02
Triglycerides (mg/dL)
CNeg 83 ± 27 56 ± 26 203 ± 335 147 ± 349 0.1 0.44
CPos 83 ± 59 134 ± 50 377 ± 201 244 ± 210 0.1 0.04
PTC 77 ± 27 205 ± 115 600 ± 556 396 ± 562 0.02 0.14
TS 51 ± 18 94 ± 44 344 ± 322 208 ± 277 0.02 0.12
PTCTS 69 ± 27 119 ± 91 386 ± 225 267 ± 139 0.35 0.005
2.7. Statistical Analyses. The quantitative variables obtained
were expressed as mean ± SD. Statistical analysis was per-
formed using SigmaStat for Windows, version 3.5.
The differences between CNeg × CPos were calculated
using Student’s 𝑡-test. Paired 𝑡-test was applied to compare
data obtained from animals of the same groups at differ-
ent collection times (pretreatment versus posttreatment) in
serum.
For comparison of serum analysis between groups, we
used the difference between the values of the pretreatment
and posttreatment sampling (Δ𝑇) using ANOVA test in order
to verify if differences were induced by the treatment.
In the group treated with PTCTS, results obtained were
comparedwith the untreated group (CPos) by Student’s 𝑡-test.
Later, PTCTS and CPOs data were compared to the other
groups by ANOVA (CPos × PTCTS × other treatments).
When ANOVA showed significant differences, the compar-
ison between groups was performed using the post hoc
Bonferroni test for data that passed the normality test and
the Dunn test for analyses that did not pass the test, always
setting the CPos as control.
In all analyses, we considered 𝑃 < 0.05 as statistically
significant.
3. Results
3.1. Lipid Profile. As shown in Table 1, the biochemical anal-
ysis of samples revealed that all groups with high cholesterol
diet had levels of TC and fractions, and TG changed between
baseline and pretreatment stages.
CPos group showed a significant increase between pre-
treatment and posttreatment regarding TC (𝑃 = 0.03), n-
HDL cholesterol (𝑃 = 0.005), and triglycerides (𝑃 = 0.04).
When compared to CNeg group, CPos increased significantly
the TC (𝑃 = 0.009) and n-HDL cholesterol levels (𝑃 = 0.002);
however, no differences were observed for the other variables
(HDL, 𝑃 = 0.82; TG, 𝑃 = 0.09) (Figure 1).
Biochemical analysis of serum from animals in the
PTCTS group showed a significant increase in TC (𝑃 = 0.02),
n-HDL (𝑃 = 0.02), and triglycerides (𝑃 = 0.005) values
and a modest decrease in the levels of HDL (𝑃 = 0.07)
when we compared the pretreatment versus posttreatment
samples. When comparing the Δ𝑇 difference between values
of lipid profile with CPos, it was noted that they did not show
any statistically significant differences (TC, 𝑃 = 0.1; HDL,
𝑃 = 0.49; n-HDL, 𝑃 = 0.18; TG, 𝑃 = 0.82).
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Table 2: Plaque measurements of the ascending aorta from animals in each group after H&E staining. Data are expressed as mean ± SD.
PE (mm) PI (mm) LP (mm2) LR (mm2) AP (mm2) AM (mm2) % Obs
CNeg 15.1 ± 1.3 12.3 ± 1.5 6.8 ± 1.6 6.8 ± 1.6 0 ± 0 5.9 ± 0.8 0 ± 0
CPos 15.1 ± 1.1 12.5 ± 1 5.9 ± 1.8 4.3 ± 1.7 2.1 ± 1.6 5.7 ± 0.4 28.6 ± 17.6
PTC 17.2 ± 1.7 14.7 ± 1.6 9.9 ± 3.1 7.3 ± 1.7 3 ± 2.6 6.7 ± 1.9 24.3 ± 11.7
TS 15.9 ± 0.6 13.2 ± 0.6 7.5 ± 2.5 5.9 ± 3 1.7 ± 1.7 6.3 ± 1.9 24.4 ± 17.7
PTCTS 17.1 ± 1.1 14.1 ± 1.3 9.7 ± 2.3 7.4 ± 2.8 2.3 ± 1.5 7.3 ± 1.1 24.5 ± 16.9
PE: external elastic lamina perimeter; PI: internal elastic lamina perimeter; AM: area of themiddle layer; LP: potential lumen of the vessel, vessel lumenwithout
the plaque; LR: real lumen of the vessel, vessel lumen with the plaque; AP: the area of atheromatous plaque;% Obs: percentage of vessel obstruction.
Table 3: Plaque measurements of thoracic and abdominal aorta from animals in each group after H&E staining. Data are expressed as mean
± SD.
Thoracic portion Abdominal portion
Total length (Et,
mm)
Plaque length
(Ep, mm)
Plaque area (AP,
mm2)
Total length (Et,
mm)
Plaque length
(Ep, mm)
Plaque area (AP,
mm2)
CNeg 10 ± 0.4 0.5 ± 1.2 0.03 ± 0.7 7.4 ± 2.0 0.1 ± 0.3 0.01 ± 0.02
CPos 9.7 ± 1.6 4.7 ± 3.6 0.8 ± 0.9 7.8 ± 2.4 4.1 ± 2.5 0.7 ± 0.8
PTC 10.6 ± 3.6 6.5 ± 3.7 1.4 ± 1.2 7.7 ± 2.8 2.6 ± 2.2 0.4 ± 0.4
TS 8.9 ± 2.2 4.4 ± 2.7 0.6 ± 0.4 8.9 ± 0.8 5 ± 3.6 1.1 ± 0.9
PTCTS 8.7 ± 1.8 3.9 ± 2.8 0.7 ± 0.4 7.6 ± 1.4 3.1 ± 2.5 0.3 ± 0.3
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Figure 1: Total cholesterol, HDL cholesterol, non-HDL cholesterol,
and triglyceride circulating levels (mg/dL) at baseline (basal),
pretreatment (pre), and posttreatment (post) collection and ΔT in
the serum of negative control (CN), positive control (CP), and
animals treated with PTCTS. Data are expressed as mean ± SD.
𝑁 = 6 in each group.
The PTC group showed no reducing effect over lipid
profile when we have compared pretreatment versus post-
treatment phases (TC, 𝑃 = 0.2; HDL, 𝑃 = 0.42; n-HDL,
𝑃 = 0.11; TG, 𝑃 = 0.14) or even when Δ𝑇 differences were
compared to CPos and PTCTS groups (TC, 𝑃 = 0.4; HDL,
𝑃 = 0.59; n-HDL, 𝑃 = 0.62; TG, 𝑃 = 0.95).
The TS group showed a lowering effect over HDL choles-
terol (𝑃 = 0.03) and increased, although not significantly,
n-HDL cholesterol (𝑃 = 0.08) between pretreatment and
posttreatment stages, with no significant changes in the other
variables (TC, 𝑃 = 0.95; TG, 𝑃 = 0.12). When comparing the
Δ𝑇 differences to CPos and PTCTS groups, TS group showed
a reduction in TC levels (𝑃 = 0.05) with no other differences
(HDL, 𝑃 = 0.32; n-HDL, 𝑃 = 0.15; TG, 𝑃 = 0.89).
3.2. Histology of the Aorta. The analysis of the ascending
aortas of animals from CPos group showed no difference
compared to CNeg group in relation to the size of the vessel
(PE, 𝑃 = 0.99; PI, 𝑃 = 0.77; LP, 𝑃 = 0.42; AM, 𝑃 =
0.73); however, they had larger plaque area (𝑃 = 0.003),
increased % Obs of the vessel (𝑃 = 0.004), and decreased
LR (𝑃 = 0.04), as shown in Table 2. Animals of CPos group
presented alterations in the middle layer areas, suggestive of
calcification.These changes were observed only in this group
(Figure 2). The analysis of the thoracic portion (Table 3)
showed that both groups, CNeg andCPos, had similar Et (𝑃 =
0.73); however, CPos rabbits showed higher Ep (𝑃 = 0.004)
and AP (𝑃 = 0.002). Similar results were observed in the
abdominal aorta (Et, 𝑃 = 0.8; Ep, 𝑃 = 0.002; AP, 𝑃 = 0.002).
Animals treated with PTCTS showed a significant
increase of PE (𝑃 = 0.01), PI (𝑃 = 0.04), LP (𝑃 = 0.01),
LR (𝑃 = 0.04), and AM (𝑃 = 0.01) when compared to CPos
group, with no differences in the other variables (AP, 𝑃 =
0.41; % Obs, 𝑃 = 0.69). The thoracic aorta of animals from
the PTCTS group showed no difference in the other variables
compared to CPos (Et, 𝑃 = 0.31; Ep, 𝑃 = 0.68; AP, 𝑃 = 0.82).
However, the abdominal aorta showed lower plaque length
and plaque area in the group treated with PTCTS (CPos, Ep,
4.07 ± 2.54; AP, 0.74 ± 0.25 versus PTCTS, Ep, 3.11 ± 2,53;
AP, 0.32 ± 0.29) although not significantly (Et, 𝑃 = 0.87; Ep,
𝑃 = 0.55; AP, 𝑃 = 0.25) (Figure 3).
The treatment of rabbits with PTC influenced the vessel
structure, by increasing the PE (𝑃 = 0.03), PI (𝑃 = 0.03), and
6 BioMed Research International
CNeg CPos PTC
TS PTCTS
Figure 2: Representative images of histological analysis (H&E staining) of the ascending portion aortas of rabbits from each group. Negative
control (CNeg), positive control (CPos), and animals treated with PTC, TS, or PTCTS.
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Figure 3: Plaque area in the ascending, thoracic, and abdominal
aortas from each group. Data are expressed as mean ± SD.𝑁 = 5-6
in each group. Negative control (CNeg), positive control (CPos), and
animals treated with PTC, TS, or PTCTS.
LR (𝑃 = 0.03) values compared to CPos and PTCTS groups
(Table 2), while the other variables did not differ (LR, 𝑃 =
0.06; AP, 𝑃 = 0.52; AM, 𝑃 = 0.06; % Obs, 𝑃 = 0.86). No
histological differences were found in the thoracic (Et, 𝑃 =
0.45; Ep,𝑃 = 0.44; AP,𝑃 = 0.33) or in the abdominal portions
of the aorta (Et, 𝑃 = 0.99; Ep, 𝑃 = 0.55; AP, 𝑃 = 0.67) in
comparison to CPos and PTCTS groups (Table 3).
Rabbits treated with TS showed no differences in the
vessel structure at histological analysis of the ascending (PE,
𝑃 = 0.39; PI, 𝑃 = 0.07; LP, 𝑃 = 0.51; LR, 𝑃 = 0.13; AP,
𝑃 = 0.63; AM, 𝑃 = 0.09; % Obs, 𝑃 = 0.89), thoracic (Et,
𝑃 = 0.61; Ep, 𝑃 = 0.91; AP, 𝑃 = 0.88), or abdominal (Et,
𝑃 = 0.43; Ep, 𝑃 = 0.6; AP, 𝑃 = 0.19) portions of aorta when
compared to CPos and PTCTS groups (Tables 2 and 3).
3.3. Immunofluorescence. The assessment of MPs positive
for M. pneumoniae and oxLDL antigens in serum showed
that even though animals were randomly distributed to the
experimental groups, animals from CPos and TS groups
already had high levels of MPs positive for M. pneumoniae
antigens (Table 4), while CNeg and TS groups had increased
numbers of MPs positive for oxLDL antigens compared to
other groups (Table 5) at the baseline.Therefore, we evaluated
the difference between the pretreatment and posttreatment
phases (Δ𝑇) to determine whether treatments influenced the
number of these MPs (Figure 4).
By doing so, it was possible to note a significant increase
in the number of both M. pneumoniae and oxLDL positive
MPs in groups between baseline collection and pretreatment
stage.
The analysis of samples from pretreatment and posttreat-
ment stages revealed that the CPos group had significantly
increased numbers of MPs positive for M. pneumoniae
(𝑃 = 0.02), as shown in Table 4; however, no significant
differences in MPs positive for oxLDL were observed (𝑃 =
0.57) (Table 5). CNeg group did not exhibit a significant
difference in any of the MPs types between pretreatment
and posttreatment stages (Tables 4 and 5). When the groups
were compared to each other, by means of Δ𝑇, it was found
that the numbers of MPs positive for M. pneumoniae were
significantly higher in CPos group compared to animals in
CNeg group (𝑃 = 0.002), while there was no difference
regarding MPs positive for oxLDL antigens (𝑃 = 0.37) as
shown in Tables 4 and 5 and Figure 4.
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Table 4: Number of circulating MPs associated withM. pneumoniae antigens in animals from each group. Data are expressed as mean ± SD.
Mycoplasma pneumoniae Basal × pre Pre × post
Basal Pretreatment Posttreatment ΔT 𝑃 𝑃
CNeg 45 ± 16 71 ± 25 49 ± 17 −22 ± 29 0.02 0.12
CPos 209 ± 104 286 ± 106 437 ± 199 152 ± 112 0.001 0.02
PTC 62 ± 42 107 ± 43 70 ± 14 −36 ± 49 0.08 0.06
TS 369 ± 243 286 ± 158 361 ± 135 75 ± 87 0.31 0.13
PTCTS 102 ± 59 296 ± 184 159 ± 103 −137 ± 88 0.02 0.01
Table 5: Number of circulating MPs associated with oxLDL in animals from each group. Data are expressed as mean ± SD.
oxLDL Basal × pre Pre × post
Basal Pretreatment Posttreatment ΔT 𝑃 𝑃
CNeg 335.3 ± 250.1 386.7 ± 232.4 301 ± 203.3 −85.7 ± 277.2 0.13 0.48
CPos 185.3 ± 112.6 305.8 ± 239.6 407.8 ± 254.6 102 ± 406.6 0.09 0.57
PTC 206.3 ± 127.4 314.7 ± 76.1 223 ± 154.1 −91.7 ± 187.1 0.07 0.28
TS 267.4 ± 171.1 261 ± 190.3 311.6 ± 169.44 50.6 ± 45.9 0.26 0.07
PTCTS 236.7 ± 120.7 350 ± 86.3 204.5 ± 57.9 −146 ± 126.6 0.05 0.04
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Figure 4: Number of circulating microparticles (MPs) associated
with antigens of Mycoplasma pneumoniae and oxLDL in animal
plasma at baseline (basal), pretreatment (pre), and posttreatment
(post) collection and Δ𝑇 in the serum of negative control (CNeg),
positive control (CPos), and animals treated with PTCTS. Data are
expressed as mean ± SD.𝑁 = 6 in each group.
The treatment of animals with PTCTS reduced the num-
ber of MPs positive for oxLDL and M. pneumoniae antigens
(Tables 4 and 5 and Figure 4) when the pretreatment and
posttreatment phases were compared (𝑃 = 0.04 and𝑃 = 0.01,
resp.), while the evaluation of Δ𝑇 showed that the treatment
had a clear effect in reducing suchMPs compared to the CPos
group (M. pneumoniae, 𝑃 < 0.001; oxLDL, 𝑃 = 0.06).
The PTC treatment was not able to reduce the number
of MPs positive for oxLDL antigens (𝑃 = 0.28) and showed
only a tendency to remove MPs positive for M. pneumoniae
antigens (𝑃 = 0.06). The comparison of Δ𝑇 showed that the
treatment of animals with PTC had no significant effect on
both MPs positive forM. pneumoniae (𝑃 > 0.05, Dunn test)
and those positive for oxLDL (𝑃 = 0.11) antigens (Tables 4
and 5).
Table 6: Weight of liver, kidneys, and spleen of animals in each
group. Data are expressed as mean ± SD.
Liver (g) Kidneys (g) Spleen (g)
CNeg 95.3 ± 20.5 22.5 ± 3.4 2.8 ± 0.7
CPos 131.4 ± 25.7 21.2 ± 6.2 3.9 ± 1.4
PTC 145.2 ± 12.5 23.9 ± 3.7 7 ± 3.4
TS 143.9 ± 24 26.8 ± 7.5 6.2 ± 2.2
PTCTS 146.8 ± 16.6 23.7 ± 2.1 5.7 ± 1.7
In comparing pretreatment versus posttreatment sera, TS
group could not significantly reduce the number of MPs
positive for oxLDL (𝑃 = 0.07) orM. pneumoniae (𝑃 = 0.13)
antigens. When comparing the Δ𝑇 differences to CPos and
PTCTS groups, TS group showed no differences in the count
of both types of MPs (𝑃 = 0.11, M. pneumoniae, t-test
Bonferroni; oxLDL, 𝑃 > 0.05, Dunn test) (Tables 4 and 5).
3.4. Histological Analysis of the Organs. Histological analysis
of liver, kidneys, and spleen of animals from CNeg group
showed normal size (Table 6) and intact structures, as well
as the absence of macroscopic lesions (Figure 5). The liver
histology analysis of animals from CNeg group showed
intact hepatocytes, space-door, arteries, ducts, and free septa,
as well as absence of inflammation, pathological changes,
or cell death (Figure 5). The kidneys had intact glomeruli
and tubules and no bleeding, lymphocyte infiltration, or
cell change (Figure 6). The spleen also showed full struc-
ture preserved red and white pulps and no infiltration of
macrophages and/or fat, with no alterations or cell death
(Figure 7).
CPos group showed organs with altered aspects, with sig-
nificantly increased size of the liver compared to CNeg group
(𝑃 = 0.02), and intense infiltration of lymphocytes, foam
cells, and the presence of fat. The kidneys of animals from
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Figure 5: Representative images of histological analysis (H&E staining) of livers of rabbits from each group. Negative control (CNeg), positive
control (CPos), and animals treated with PTC, TS, or PTCTS. Magnification, ×10.
CNeg CPos PTC
TS PTCTS
Figure 6: Representative images of histological analysis (H&E staining) of kidneys of rabbits from each group. Negative control (CNeg),
positive control (CPos), and animals treated with PTC, TS, or PTCTS. Magnification, ×10.
CPos group showed lymphocyte infiltration, the presence of
fat, and typical cell change of fibrotic process, while the spleen
contained xanthomatous macrophage and fat infiltration,
besides presenting diffusion of red and white pulps.
The group treated with PTCTS showed livers with vacuo-
lated hepatocytes, lymphocyte infiltration, and discrete pres-
ence of foam cells and fat to a lesser extent when compared
to CPos. The kidneys of these animals contained discrete
fat infiltration and mild bleeding, with intense lymphocytic
infiltrate in the renal tubules, while the glomeruli showed no
changes, similar to CNeg. In the spleen of animals from this
group, discrete infiltration of foam cells was noted, with white
and red pulps intact when compared to CNeg and CPos.
In animals from the PTC group, liver presented with
lower presence of fat and xanthomatous macrophages but
with intense lymphocytic infiltrate. A similar effect on the
kidneys was noted, while spleen contained a moderate infil-
tration of foam cells and dispersion of red and white pulps.
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Figure 7: Representative images of histological analysis (H&E staining) of spleen of rabbits fromeach group.Negative control (CNeg), positive
control (CPos), and animals treated with PTC, TS, or PTCTS. Magnification, ×10.
Animals treated with TS showed lymphocytic and foam
cells with moderate infiltration in the liver, kidneys, and
spleen; the latter showed moderate dispersion of red and
white pulps.
4. Discussion
Atherosclerosis is the consequence of the accumulation of
monocytes and macrophages that invade the subendothelial
space attracted by the presence of oxLDL.Thephagocytosis of
oxLDL particles by macrophages gives rise to xanthomatous
cells, the base of the formation of atheroma [18].
Previous studies from our group showed that antigens
and forms compatible with the bacteria M. pneumoniae and
Chlamydophila pneumoniae were observed in atherosclerotic
plaques and were even presenting larger amounts in ruptured
plaques, which are responsible for acute myocardial infarc-
tion [15]. The presence of MPs in intimate contact with the
bacteria was also described [19], as well as in circulating blood
of infarcted patients [20, 21].
The present study evaluated whether MPs containingM.
pneumoniae and oxLDL antigens are present in circulating
blood from rabbits fed high cholesterol diet for 12 weeks and
whether these MPs could be playing a role in the progression
of the disease.
We also tested the impact of MP removal by the treat-
ment of animals with PTCTS, a drug that was developed
by H&S Science and Biotechnology, on the progression of
atherosclerosis. We also assessed the effect of the individual
components of PTCTS, PTC and TS, on the numbers of
circulating MPs and the progression of atherosclerosis in
rabbits. The cytotoxic effects of these compounds were also
evaluated in key target organs (liver, kidneys, and spleen).
Before the start of the treatments with the compounds,
it was possible to note that, as expected, the hypercholes-
terolemic diet increased serum levels of total cholesterol and
its fractions in animals that were exposed to the diet in
comparison to baseline.
In addition, we noted that there was an increase in serum
MPs positive for M. pneumoniae and oxLDL antigens, even
in CPos, which already had high baseline levels of MPs,
indicating that Mycoplasmas and Mycoplasma-derived MPs
may play a role in the development of atherosclerotic disease.
The treatment of animals with PTCdid not show any lipid
lowering properties when pretreatment and posttreatment
stages were compared or in comparison to CPos and PTCTS
groups. However, PTC could reduce the number of MPs pos-
itive for M. pneumoniae antigens, although not significantly,
when we compared between pretreatment and posttreatment
stages. Furthermore, PTC did not affect the number of MPs
positive for oxLDL in comparison to animals from CPos and
PTCTS groups.
In addition, the PTC treatment did not show a significant
antiatherosclerotic effect since it was not capable of reducing
plaque area in the ascending aorta, location known to bemore
affected by atherosclerotic disease, together with the aortic
arch, due to high pressure blood and therefore more likely
to exhibit endothelial injury [22]. However, the analysis of
abdominal aorta showed a lesser plaque formation, although
this was not statistically significant. This could be explained
by the lower blood pressure and endothelial damage in this
vascular territory as well as being the closest region to the site
of uptake of organic particles, making thus this anatomical
site the one showing the most visible effect of PTC.
Importantly, PTC treatment also showed important dif-
ferences in the structure of the aorta with larger values
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of the external and internal perimeters compared to CPos,
indicating that the vessel diameter in this groupof the animals
was greater. Such data associatedwith the potential and actual
lumen values larger than the animals from CPos group, even
with similar plaque area values, are indicative of positive
remodeling, a phenomenon described by Glasgov et al. [23],
in 1987, as compensatory enlargement of the coronary arteries
to accommodate large quantities of atheromatous plaque,
thus permitting the maintenance of blood flow.
The treatment of animals with TS significantly reduced
serumHDL levels, althoughTG, n-HDLcholesterol, and total
cholesterol levels remained high, which could be considered
as a step towards an antilipidemic action. However, given
alone, TS did not show any antiatherosclerotic effects in any
of the analyzed portions of the aorta.
A negative correlation was previously observed between
sialic acid levels of LDL and the capacity of these lipoprotein
particles to cause intracellular accumulation of cholesterol
[24]. Compared to native LDL, desialylated LDL has a
higher capacity to bind to asialoglycoprotein receptor, a
high capacity C-type lectin receptor, mainly expressed on
hepatocytes. The interaction of desialylated LDL particles
with this scavenger receptor leads to their uptake by the
cell and hence to their intracellular accumulation due to
reduced degradation [25]. The removal of sialic acid from
LDL by neuraminidase was also found to enhance the
atherogenic potential of LDL particles by increasing their
capacity to accumulate intracellular cholesterol content in
smooth muscle cells and macrophages [26]. Work by Tertov
et al. [27] has later shown that human serum contained active
TS and that the treatment of native (sialylated) LDL particles
with TS caused desialylation of 60% of the LDL particles.
When smoothmuscle cells fromhealthy human aortic intima
were exposed to TS-treated LDL particles, the intracellular
cholesterol content significantly increased compared to cells
treated with native LDL, indicating a proatherogenic poten-
tial for TS through its capacity to modify LDL and increase
its intracellular uptake [27]. In our hands, and at the concen-
tration used [1.62 × 10−7mg/mL, 100 𝜇L/day], TS treatment
was associated with a small antilipidemic effect and did not
cause any further worsening of atherosclerosis in cholesterol-
fed animals. Although an effect of the administered TS on
circulating LDL particles cannot be completely ruled out, the
daily dose of TS administered to rabbits in our study is very
low compared to the concentration of TS which was shown to
cause amodification of LDL particles [27].Therefore, one can
anticipate that, at the concentration used in our formulation,
TS may not cause significant modifications of LDL particles
and thus an important increase in the proportion of desia-
lylated LDL; however, further investigation is warranted for
confirmation.
Furthermore, the administration of TS alone showed no
ability to remove MPs positive forM. pneumoniae or oxLDL
antigens in circulating blood.This could be, partly, explained
by the instability of TS in the acid pHof the stomach after oral
administration.
We found here, however, that the combination of PTC
and TS, PTCTS, was effective at several levels in atheroscle-
rotic rabbits such as in removing MPs positive for oxLDL
and M. pneumoniae antigens in the serum of rabbits after
treatment and in lowing lipid levels, two factors of paramount
importance in the development of antiatherogenic and anti-
inflammatory response.
Furthermore, PTCTS demonstrated positive effects on
the structure of the aorta by inducing changes in the vessel
size as compared to negative and positive controls. These
differences are again indicative of positive remodeling such
as the one observed in the PTC group.
Evenwith no effects over the composition of the plaque or
its vulnerability, the treatment of rabbits with PTCTS could
reduce, although not significantly, the amount of plaque
present in the abdominal portion of the aorta, suggesting
a more effective antiatherosclerotic effect compared to PTC
alone. The effects of treatment of rabbits with TS were
different from those of the treatment with PTC; however,
the effects of PTCTS presented characteristics from both
components, indicating that the combination of the two
components together is complementary.
The initiation of this study was based on previous work
from our group, in which the PTCTS was administered
intramuscularly to atherosclerotic rabbits and could remove
almost completely plaque area in both the thoracic and
abdominal portions or the aorta, as well as at the ascending
aorta, while reducing the serum total cholesterol and its
fractions and bringing them back to baseline levels [28].
However, the oral administration of the same compound did
not produce the exact same results.
It is known that oral administration of medications has
many advantages, such as the fact that it is a safe and
practical way that allows self-administration as well as being
more economical; however, it also has some disadvantages
that should be taken into consideration. For instance, the
absorption can range from moderate to low as well as high
likelihood of partial loss of the drug by inactivation of the
active ingredients due to the action of gastric enzymes and
acid pH, while intramuscular route of administration is rapid
and has systemic absorption.
The difference in the results with respect to antilipidemic
and antiatherosclerotic actions of PTCTS may be due to
either lesser plasma bioavailability with oral administration
because of incomplete absorption or loss of some of the
activity caused by the action of gastric enzymes.
Therefore, it is warranted to devise future pharmacoki-
netic studies to adjust the dose, treatment time, and delivery
vehicle such that the compound holds its integrity even in the
low pH environment of the stomach.We are currently testing
the application of the compound in a stabilizing gel, which
may eventually be included in gelatin capsules, allowing for
a higher concentration of the drug to reach the bloodstream
and target organs.
In conclusion, we have observed here that PTCTS com-
ponents have different effects when administered alone. PTC
treatment caused positive remodeling of the vessel, while the
TS had lipid lowering effects with reduced TC in addition to
the elimination of MPs positive forM. pneumoniae antigens.
When combined, the PTC and TS complemented the
action of each other, allowing PTCTS to achieve more
comprehensive actions and leading to a better therapeutic
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result, by improving lipid and liver profiles, the elimination
of MPs, and causing positive vascular remodeling.
It is clearly warranted that, in order to achieve optimal
results against atherosclerosis comparable to subcutaneously
injected PTCTS, it is important to optimise the dosage,
formulation, and the period of treatment for oral use of
PTCTS.
Altogether, the findings reported in the present study
reinforce the infectious theory of the pathogenesis of
atherosclerosis and underscore the potential key role of
circulatingMPs originating from suchmicroorganisms in the
development of the disease. Therefore, the removal of these
MPs from blood could be a new therapeutic approach in the
treatment of atherosclerosis.
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